Exact Sciences (EXAS) Competitors $56.89 -0.92 (-1.59%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$56.94 +0.05 (+0.10%) As of 05/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. ALNY, BIIB, UTHR, INCY, EXEL, NBIX, BMRN, RGEN, HALO, and MDGLShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Exelixis Neurocrine Biosciences BioMarin Pharmaceutical Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability. Does the media favor ALNY or EXAS? In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Exact Sciences. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 14 mentions for Exact Sciences. Alnylam Pharmaceuticals' average media sentiment score of 1.33 beat Exact Sciences' score of 1.31 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 14 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ALNY or EXAS? Alnylam Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Do analysts prefer ALNY or EXAS? Alnylam Pharmaceuticals currently has a consensus target price of $319.17, suggesting a potential upside of 9.09%. Exact Sciences has a consensus target price of $70.90, suggesting a potential upside of 24.63%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 Does the MarketBeat Community believe in ALNY or EXAS? Alnylam Pharmaceuticals received 173 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.32% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.14% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes116776.32% Underperform Votes36223.68% Exact SciencesOutperform Votes99473.14% Underperform Votes36526.86% Which has preferable earnings & valuation, ALNY or EXAS? Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.35B16.25-$278.16M-$2.09-139.99Exact Sciences$2.83B3.79-$204.15M-$5.51-10.32 Is ALNY or EXAS more profitable? Alnylam Pharmaceuticals has a net margin of -12.37% compared to Exact Sciences' net margin of -37.29%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Exact Sciences -37.29%-5.29%-2.45% Do institutionals and insiders believe in ALNY or EXAS? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Exact Sciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Exact Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAlnylam Pharmaceuticals beats Exact Sciences on 11 of the 19 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.73B$2.92B$5.37B$8.39BDividend YieldN/A31.24%5.22%4.10%P/E Ratio-10.2112.8626.8419.71Price / Sales3.79160.59392.34117.39Price / Cash8.7957.5638.2534.62Price / Book4.404.276.794.50Net Income-$204.15M-$22.21M$3.23B$248.18M7 Day Performance1.28%1.91%1.53%0.20%1 Month Performance28.86%2.20%10.06%12.37%1 Year Performance6.36%1.41%16.72%7.04% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.2842 of 5 stars$56.89-1.6%$70.90+24.6%+6.3%$10.73B$2.83B-10.216,400Positive NewsALNYAlnylam Pharmaceuticals3.6635 of 5 stars$291.86+2.3%$319.17+9.4%+95.5%$38.06B$2.35B-134.502,000Positive NewsBIIBBiogen4.8992 of 5 stars$129.44+3.1%$191.30+47.8%-44.3%$18.97B$9.82B11.578,720Positive NewsAnalyst RevisionUTHRUnited Therapeutics4.978 of 5 stars$305.310.0%$392.00+28.4%+12.5%$13.77B$2.99B13.41980Positive NewsINCYIncyte4.8743 of 5 stars$63.81+0.8%$73.53+15.2%+12.9%$12.35B$4.41B236.342,320Positive NewsEXELExelixis4.1177 of 5 stars$44.69-1.6%$38.94-12.9%+108.0%$12.19B$2.30B25.251,220NBIXNeurocrine Biosciences4.9182 of 5 stars$122.82+1.5%$162.00+31.9%-14.2%$12.16B$2.41B37.331,200Positive NewsBMRNBioMarin Pharmaceutical4.9924 of 5 stars$59.41+0.2%$93.45+57.3%-24.4%$11.39B$2.95B27.003,080Positive NewsInsider TradeRGENRepligen4.7864 of 5 stars$126.19-0.2%$173.25+37.3%-28.0%$7.09B$650.43M-247.432,020Positive NewsGap UpHALOHalozyme Therapeutics4.8553 of 5 stars$53.29+2.4%$61.90+16.2%+18.4%$6.57B$1.08B15.54390MDGLMadrigal Pharmaceuticals4.5986 of 5 stars$290.72-0.1%$416.33+43.2%+14.3%$6.45B$317.38M-11.5990Positive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Exelixis Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts